Literature DB >> 8503379

Predictors and the rate of medical treatment failure in ulcerative colitis.

B J Chakravarty1.   

Abstract

Eighty-nine admissions into Auckland Hospital with exacerbation of ulcerative colitis (between May 1985 and May 1991) were analyzed to determine the rate and any predictors of medical treatment failure. Twenty-five patients (28%) failed to respond to medical treatment and required surgery. Clinical information and laboratory indices available within 24 h of the admissions were compared between the patients requiring surgery and those who did not. There were no significant differences between the groups in sex distribution, age of onset of disease, duration of disease, hemoglobin concentration, or white cell count. However, "severe" diarrhea (chi 2 = 24.83, p = 0.0001), and lower albumin level (F1, 83 = 45.61, p = 0.0001) were noted in the surgical group. There was a tendency toward higher ESR (F1, 82 = 3.06, p = 0.08) and "extensive" colitis (chi 2 = 3.29, p = 0.07) in the patients requiring surgery. Univariate analysis confirmed albumin level and severity of diarrhea as significant discriminators. A discriminant function analysis showed that albumin level and severity of diarrhea would distinguish between surgical and nonsurgical outcome in 82% of cases. Distal colitis and mild to moderate diarrhea had negative predictive values of 80% and 91%, respectively, for nonsurgical outcome of acute ulcerative colitis. It is concluded that the above significant variables are good predictors of outcome of medical treatment for exacerbations of ulcerative colitis and that the proportion of patients needing surgery has not changed in the last 35 yr despite various management strategies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8503379

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  13 in total

1.  Prediction of short-term outcome for patients with active ulcerative colitis.

Authors:  N Oshitani; T Matsumoto; Y Jinno; Y Sawa; J Hara; S Nakamura; T Arakawa; A Kitano; T Kuroki
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

2.  Cytomegalovirus complicating inflammatory bowel disease: a 10-year experience in a community-based, university-affiliated hospital.

Authors:  Raed Al-Zafiri; Adrian Gologan; Polymnia Galiatsatos; Andrew Szilagyi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-04

3.  Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis.

Authors:  Han Ho Jeon; Hyun Jung Lee; Hui Won Jang; Jin Young Yoon; Yoon Suk Jung; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

4.  Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes.

Authors:  S D Hearing; M Norman; C S Probert; N Haslam; C M Dayan
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

5.  Cytomegalovirus infection in patients with active inflammatory bowel disease.

Authors:  John J Kim; Nicole Simpson; Nancy Klipfel; Renee Debose; Nancy Barr; Loren Laine
Journal:  Dig Dis Sci       Date:  2010-01-29       Impact factor: 3.199

6.  Predictors of clinical response to systemic steroids in active ulcerative colitis.

Authors:  Isabel Bernal; Míriam Mañosa; Eugeni Domènech; Esther Garcia-Planella; Mercè Navarro; Vicente Lorenzo-Zúñiga; Eduard Cabré; Miquel Angel Gassull
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

7.  Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors.

Authors:  Shigeki Bamba; Akira Andoh; Hirotsugu Imaeda; Hiromitsu Ban; Ayako Kobori; Yousuke Mochizuki; Makoto Shioya; Takashi Nishimura; Osamu Inatomi; Masaya Sasaki; Yasuharu Saitoh; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  Exp Ther Med       Date:  2012-04-11       Impact factor: 2.447

Review 8.  Steroid-refractory severe ulcerative colitis: what are the available treatment options?

Authors:  Alan C Moss; Mark A Peppercorn
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Promising effect of infliximab on the extent of involvement in ulcerative colitis.

Authors:  Peyman Adibi; Pejman Mollakhalili; Zahra Fallah; Nasser Ebrahimi Daryani; Hossein Ajdarkosh; Hossein Khedmat; Faramarz Derakhshan; Ashraf Karbassi; Mahshid Ashkzari; Hamid Tavakkoli
Journal:  J Res Med Sci       Date:  2011-01       Impact factor: 1.852

10.  Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis.

Authors:  Jaeyoung Chun; Changhyun Lee; Ji-Eun Kwon; Sung Wook Hwang; Sang Gyun Kim; Joo Sung Kim; Hyun Chae Jung; Jong Pil Im
Journal:  Intest Res       Date:  2015-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.